A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT03360006
- Locations
- 🇺🇸
UC Irvine /ID# 160789, Orange, California, United States
🇺🇸University of California, Davis Comprehensive Cancer Center /ID# 202729, Sacramento, California, United States
🇺🇸Northwestern /ID# 171098, Chicago, Illinois, United States
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03356080
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: APX001 with Standard of Care anti-fungal agent
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 20
- Registration Number
- NCT03333005
- Locations
- 🇩🇪
University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
🇩🇪Johannes Gutenberg, University of Mainz, Mainz, Germany
🇩🇪University of Munich, Grosshadern Campus, Munich, Germany
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03315039
- Locations
- 🇺🇸
UC San Diego Health, La Jolla, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03303339
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03298516
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03298984
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
- Conditions
- MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Non-Hodgkin's LymphomaNeuroblastoma
- Interventions
- Drug: chemotherapy
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 143
- Registration Number
- NCT03236857
- Locations
- 🇺🇸
Univ California, San Francisco /ID# 163460, San Francisco, California, United States
🇺🇸Children's Hospital Colorado /ID# 161551, Aurora, Colorado, United States
🇺🇸Children's Healthcare of Atlan /ID# 161552, Atlanta, Georgia, United States
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT03224819
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: AZD5991 + Venetoclax
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT03218683
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States